Safety of ipsapirone treatment compared with lorazepam: Discontinuation effects

Journal of Psychiatry and Neuroscience

Volumn 23, Issue 1, 1998, Pages 35-44

  Busto, Usoa E ^a   Naranjo, Claudio A ^b   Bremner, Karen E ^b   Peachey, John E ^b   Bologa, Monica ^b  

^a UNIVERSITY OF TORONTO   (Canada)

^b NONE

Author keywords

Anti anxiety agents; Benzodiazepine; Lorazepam; Substance dependence; Substance withdrawal syndrome

Indexed keywords

BENZODIAZEPINE DERIVATIVE; IPSAPIRONE; LORAZEPAM; SEROTONIN 1A AGONIST;

ADULT; ANOREXIA; ARTICLE; ASTHENIA; CLINICAL TRIAL; CONTROLLED STUDY; DOUBLE BLIND PROCEDURE; DRUG SAFETY; HEADACHE; HUMAN; MALE; NAUSEA; NORMAL HUMAN; RANDOMIZED CONTROLLED TRIAL; SLEEP; SYMPTOMATOLOGY; VERTIGO; WITHDRAWAL SYNDROME; XEROSTOMIA;

ADULT; ANTI-ANXIETY AGENTS; DOUBLE-BLIND METHOD; HUMANS; LORAZEPAM; MALE; PROSPECTIVE STUDIES; PYRIMIDINES; SUBSTANCE WITHDRAWAL SYNDROME;

EID: 0031917952     PISSN: 11804882     EISSN: None     Source Type: Journal    
DOI: None     Document Type: Article

References (35)

1. Shader RI, Greenblatt DJ. Use of benzodiazepines in anxiety disorders. N Engl J Med 1993;328:1398-405.
2. Rickels K, Schweizer E, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. I. Effects of abrupt discontinuation. Arch Gen Psychiatry 1990;47:899-907.
3. Schweizer E, Rickels K, Case WG, Greenblatt DJ. Long-term therapeutic use of benzodiazepines. II. Effects of gradual taper. Arch Gen Psychiatry 1993;150:1210-5.
4. Greenblatt DJ, Miller LG, Shader RI. Benzodiazepine discontinuation syndromes. J Psychiatr Res 1990;24:73-9.
5. Kales A, Soldatos CR, Bixler JD. Early morning insomnia with rapidly eliminated benzodiazepines. Science 1983;220:95-7.
6. Busto UE, Sellers EM, Naranjo CA, Cappell H, Sanchez-Craig M, Sykora K. Withdrawal reaction after long-term therapeutic use of benzodiazepines. N Engl J Med 1986;315:854-9.
7. Woods JH, Katz JL, Winger GD. Benzodiazepines: use, abuse, and consequences. Pharmacol Rev 1992;44:151-347.
8. Schweizer E, Rickels K, Uhlenhuth EH. Issues in the long-term treatment of anxiety disorders. In: Bloom FE, Kupfer DJ, editors. Psychopharmacology: the fourth generation of progress. New York: Raven Press;1995. p. 1349-59.
9. Lader MH. Ondansetron in the treatment of anxiety. In: Proceedings of the Satellite Symposiun of the 5th World Congres of Biological Psychiatry; 1991; Florence, Italy, p. 16-9.
10. Stephens DN, Schneider H, Kehr W, et al. Abecarnil, a metabolically stable anxioselective carboline acting at benzodiazepine receptors. J Pharmacol Exp Ther 1990;253:334-43.
11. Rickels K, Schweizer E, Csanasoli I, Case WG, Chung H. Longterm treatment of anxiety and the risk of withdrawal. Prospective comparison of clorazepate and buspirone. Arch Gen Psychiatry 1988;45:444-50.
12. Rakel RE. Long-term buspirone therapy for chronic anxiety: a multicenter international study to determine safety. South Med J 1990;83:194-8.
13. Borison RL, Albrecht JW, Diamond BI. Efficacy and safety of a putative anxiolytic agent: ipsapirone. Psychopharmacol Bull 1990;26:207-10.
14. Lesch KP, Wiesmann M, Hoh A, et al. 5-HT1A receptor-effector system responsivity in panic disorder. Psychopharmacology 1992;106:111-7.
15. Cutler NR, Keppel Hesselink JM, Sramek JJ. A phase II multicenter dose-finding efficacy and safety trial of ipsapirone in outpatients with generalized anxiety disorders. Prog Neuro-Psychopharmacol Biol Psychiatr 1994;18:447-63.
16. Keppel Hesselink JM. Promising anxiolytics? A new class of drugs: the azapirones. In: Stahl SM, Gatspar M, Keppel Hesselink JM, editors. Scrotonin IA receptors in depression and anxiety. New York: Raven Press, 1992, p. 171-83.
17. Miles Canada Inc. Clinical study protocol. Etobicoke (ON): Miles Canada Inc.; 1991.
18. Feighner JP, Boyer WF. Serotonin-1A anxiolytics: an overview. Psychopathology 1989;22(suppl):21-6.
19. Goudie AJ, Leathley M, McNally J. Comparative effects on body weight, food intake and temperature of withdrawal from ipsapirone and chlordiazepoxide in rats [abstract]. Br J Pharmacol 1989;96:308P.
20. Busto U, Currie N, Kwok M, Kalvik A, Naranjo CA. Compliance with medication in clinical trials: implications for data interpretation [abstract]. Clin Pharmacol Ther 1994;55:156.
21. Kalvik A, Kwok M, Tseng A, Currie N, Busto U, Naranjo CA. Variations in Medication Events Management Systems (MEMS) performance [abstract]. Clin Pharmacol Ther 1994;55;157.
22. Hamilton M. Diagnosis and rating of anxiety. Br J Psychiatr 1969;Special Publication No. 3:76-9.
23. Hamilton M. Development of a rating scale for primary depressive illness. Br J Soc Clin Psychol 1967;6:278-96.
24. Spielberger CD, Gorsuch RL, Lushene RR. Manual for the State-Trait Anxiety Inventory (self-evaluation questionnaire). Palo Alto (CA): Consulting Psychologists Press Inc.; 1970.
25. Busto UE, Sykora K, Sellers EM. A clinical scale to assess benzodiazepine withdrawal. J Clin Psychopharmacol 1989;9:412-6.
26. Cutler NR, Sramek JJ, Hesselink JK, et al. A double-blind, placebo-controlled study comparing the efficacy and safety of ipsapirone versus lorazepam in subjects with generalized anxiety disorder: a prospective multicenter trial. J Clin Psychopharmacol 1993;13:429-37.
27. Ashton H. Benzodiazepine withdrawal: an unfinished story. BMJ 1984;288:1133-40.
28. Kales A, Scharf MB, Kales JD. Rebound insomnia: a new clinical syndrome. Science 1978;201:1039-41.
29. Vogel GW, Barber K, Gibbons P, Thurmond A. A comparison of the effects of flurazepam 30 mg and triazolam 0.5 mg on the sleep of insomniacs, Psychopharmacology 1976;47:81-6.
30. Greenblatt DJ, Harmatz J, Zimni MA, Shader RI. Effect of gradual withdrawal on the rebound sleep disorder after discontinuation of triazolam. N Engl J Med 1987;317:722-8.
31. Pecknold JC, Swinson RD. Taper withdrawal studies with alprazolam in patients with panic disorder and agoraphobia. Psychopharmacol Bull 1986;21:173-6.
32. Cramer JA. Overview of methods to measure and enhance patient compliance. In: Cramer JA, Spilker B, editors. Patient compliance in medical practice and clinical trials. New York: Raven Press; 1991. p. 3-10.
33. Feinstein AR. "Compliance bias" and the interpretation of therapeutic trials. In: Haynes RB, Taylor DW, Sackett UL, editors. Compliance in health care. Baltimore (MD): Johns Hopkins University Press; 1979, p. 309-22.
34. Cutler NR, Sramek JJ, Wardle TS, et al. The safety and efficacy of ipsapirone vs. lorazepam in outpatients with generalized anxiety disorder (CAD), single site findings from a multicentre trial. Psychopharmacol Bull 1993;29:303-8.
35. Mandos LA, Rickets K, Cutler N, et al. Placebo-controlled comparison of the clinical effects of rapid discontinuation of ipsapirone and lorazepam after 8 weeks of treatment for generalized anxiety disorder. Int Clin Psychopharmacol 1995;10:251-6.